Suzanne Trudel is a Full Professor of Medicine at the University of Toronto and a Clinician Scientist and Staff Hematologist at Princess Margaret Cancer Centre. Dr Trudel is has previously served as a member of the steering committee of the Multiple Myeloma Research Consortium (MMRC) and a member of the subcommittee on Plasma Cell biology for the American Society of Hematology (ASH). She is currently a special expert member of the National Cancer Institute myeloma steering committee, and a member of Myeloma Canada advisory board. Her research focus has been in the areas novel drug development which involved identification and validation of new therapeutic targets, development of novel platforms to support clinical trials of personalized medicine and Phase I/II clinical trials. Dr Trudel’s work has been published in numerous referenced journals including the New England Journal of Medicine, Nature Medicine, Lancet Oncology, Nature Communications, the Journal of Clinical Oncology and Blood.

Geoff Hill is a medical graduate of the University of Auckland and Hematologist, training in New Zealand and The Dana Farber Cancer Institute in Boston. He was the PI of a large transplant immunology laboratory and a Transplant Physician in Brisbane, Australia between 2000 and 2018 which focused on the interactions between cytokines, antigen presenting cells and T cell differentiation. His laboratory developed a number of seminal paradigms in the field that have instructed clinical practice and have been published in NEJM, Science, Nature Medicine, Immunity, Nature Immunology, Science Immunology and Blood. His work has identified new therapeutics that have now been FDA approved. Prof. Hill moved to The Fred Hutchinson Cancer Center in Seattle, USA in 2018 to take up the Jose Carreras/E. Donnall Thomas Endowed Chair for Cancer Research and the Director role for Hematopoietic Stem Cell Transplantation. He is also Senior Vice President and the Head of the Translational Science and Therapeutics Division at Fred Hutch. Within the USA, his laboratory has developed new multiome, in vivo imaging with classical immunology approaches to study aberrant and tumor-specific immune responses in tissue after both transplantation and cell therapy that have led to a number of new NIH-funded preclinical and translational clinical studies.

Born in Hungary, 1945. Arrived in NZ in 1957 as sponsored refugee. Graduated from Otago University Medical School in 1970. Internship in Christchurch. Commenced training in Haematology. Migrated to Australia in 1975. Completed Haematology training. Main interests, multiple myeloma and amyloidosis.